Key statistics
As of last trade BIOGEN DRN (BIIB34:SAO) traded at 168.98, 0.31% above its 52-week low of 168.45, set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 168.98 |
---|---|
High | 168.98 |
Low | 168.98 |
Bid | 167.45 |
Offer | 168.64 |
Previous close | 169.15 |
Average volume | 45.57 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Oct 07 2024 15:04 BST.
More ▼
- UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
- Biogen Board Appoints Two New Independent Directors
- Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
- Biogen Completes Acquisition of Human Immunology Biosciences
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
- TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
More ▼